PURPOSE: Published series of growth rates of renal tumors on active surveillance largely consist of tumors without pathologic or genetic data. Growth kinetics of genetically defined renal tumors are not well known. Here, we evaluate the growth of genetically defined renal tumors and their association with patient clinical and genetic characteristics. PATIENTS AND METHODS: We evaluated patients with an inherited kidney cancer susceptibility syndrome as a result of a pathologic germline alteration of VHL, MET, FLCN, or BAP1 with at least 1 solid renal mass managed with active surveillance at our institution. Tumor growth rates (GR) were calculated and patients were stratified by genetic alteration and other clinical and genetic factors to analyze differences in growth rates using linear regression and comparative statistics. RESULTS: A total of 292 patients with 435 genetically defined tumors were identified, including 286 VHL-deficient, 91 FLCN-deficient, 52 MET-activated, and 6 BAP1-deficient tumors. There were significant differences in GRs when stratified by genetic alteration. BAP1-deficient tumors had the fastest median GR (0.6 cm/y; interquartile range [IQR], 0.57-0.68 cm/y), followed by VHL-deficient tumors (GR, 0.37 cm/y; IQR, 0.25-0.57 cm/y), FLCN-deficient tumors (GR, 0.10 cm/y; IQR, 0.04-0.24 cm/y), and tumors with MET activation (GR, 0.15 cm/y; IQR, 0.053-0.32 cm/y; P < .001). Tumors from the same patient had similar GRs. Younger age was independently associated with higher GR (P = .005). CONCLUSION: In a cohort of genetically defined tumors, tumor growth rates varied in a clinically and statistically different manner according to genetic subtype. Rapid growth of BAP1-deficient tumors indicates that these patients should be managed with caution. The faster growth of tumors in younger patients may support more frequent imaging, whereas the slower growth of other tumors may support extended surveillance beyond annual imaging in some instances.
PURPOSE: Published series of growth rates of renal tumors on active surveillance largely consist of tumors without pathologic or genetic data. Growth kinetics of genetically defined renal tumors are not well known. Here, we evaluate the growth of genetically defined renal tumors and their association with patient clinical and genetic characteristics. PATIENTS AND METHODS: We evaluated patients with an inherited kidney cancer susceptibility syndrome as a result of a pathologic germline alteration of VHL, MET, FLCN, or BAP1 with at least 1 solid renal mass managed with active surveillance at our institution. Tumor growth rates (GR) were calculated and patients were stratified by genetic alteration and other clinical and genetic factors to analyze differences in growth rates using linear regression and comparative statistics. RESULTS: A total of 292 patients with 435 genetically defined tumors were identified, including 286 VHL-deficient, 91 FLCN-deficient, 52 MET-activated, and 6 BAP1-deficient tumors. There were significant differences in GRs when stratified by genetic alteration. BAP1-deficient tumors had the fastest median GR (0.6 cm/y; interquartile range [IQR], 0.57-0.68 cm/y), followed by VHL-deficient tumors (GR, 0.37 cm/y; IQR, 0.25-0.57 cm/y), FLCN-deficient tumors (GR, 0.10 cm/y; IQR, 0.04-0.24 cm/y), and tumors with MET activation (GR, 0.15 cm/y; IQR, 0.053-0.32 cm/y; P < .001). Tumors from the same patient had similar GRs. Younger age was independently associated with higher GR (P = .005). CONCLUSION: In a cohort of genetically defined tumors, tumor growth rates varied in a clinically and statistically different manner according to genetic subtype. Rapid growth of BAP1-deficient tumors indicates that these patients should be managed with caution. The faster growth of tumors in younger patients may support more frequent imaging, whereas the slower growth of other tumors may support extended surveillance beyond annual imaging in some instances.
Authors: Maria I Carlo; Semanti Mukherjee; Diana Mandelker; Joseph Vijai; Yelena Kemel; Liying Zhang; Andrea Knezevic; Sujata Patil; Ozge Ceyhan-Birsoy; Kuo-Cheng Huang; Almedina Redzematovic; Devyn T Coskey; Carolyn Stewart; Nisha Pradhan; Angela G Arnold; A Ari Hakimi; Ying-Bei Chen; Jonathan A Coleman; David M Hyman; Marc Ladanyi; Karen A Cadoo; Michael F Walsh; Zsofia K Stadler; Chung-Han Lee; Darren R Feldman; Martin H Voss; Mark Robson; Robert J Motzer; Kenneth Offit Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Christian P Pavlovich; Robert L Grubb; Kathleen Hurley; Gladys M Glenn; Jorge Toro; Laura S Schmidt; Carlos Torres-Cabala; Maria J Merino; Berton Zbar; Peter Choyke; McClellan M Walther; W Marston Linehan Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Alberto Cascón; Beatriz Escobar; Cristina Montero-Conde; Cristina Rodríguez-Antona; Sergio Ruiz-Llorente; Ana Osorio; Fátima Mercadillo; Rocío Letón; José M Campos; José M García-Sagredo; Javier Benítez; Marcos Malumbres; Mercedes Robledo Journal: Hum Mutat Date: 2007-06 Impact factor: 4.878
Authors: Michael A S Jewett; Kamal Mattar; Joan Basiuk; Christopher G Morash; Stephen E Pautler; D Robert Siemens; Simon Tanguay; Ricardo A Rendon; Martin E Gleave; Darrel E Drachenberg; Raymond Chow; Hannah Chung; Joseph L Chin; Neil E Fleshner; Andrew J Evans; Brenda L Gallie; Masoom A Haider; John R Kachura; Ghada Kurban; Kimberly Fernandes; Antonio Finelli Journal: Eur Urol Date: 2011-04-01 Impact factor: 20.096
Authors: Laura S Schmidt; Michael L Nickerson; Debora Angeloni; Gladys M Glenn; McClellan M Walther; Paul S Albert; Michelle B Warren; Peter L Choyke; Carlos A Torres-Cabala; Maria J Merino; Joan Brunet; Victòria Bérez; Joan Borràs; Giovanni Sesia; Lindsay Middelton; John L Phillips; Catherine Stolle; Berton Zbar; Stephen E Pautler; W Marston Linehan Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Jodi K Maranchie; Anoushka Afonso; Paul S Albert; Sivaram Kalyandrug; John L Phillips; Shubo Zhou; James Peterson; Bijan M Ghadimi; Katheen Hurley; Joseph Riss; James R Vasselli; Thomas Ried; Berton Zbar; Peter Choyke; McClellan M Walther; Richard D Klausner; W Marston Linehan Journal: Hum Mutat Date: 2004-01 Impact factor: 4.878
Authors: Robert L Grubb; Michael E Franks; Jorge Toro; Lindsay Middelton; Lynda Choyke; Sarah Fowler; Carlos Torres-Cabala; Gladys M Glenn; Peter Choyke; Maria J Merino; Berton Zbar; Peter A Pinto; Ramaprasad Srinivasan; Jonathan A Coleman; W Marston Linehan Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Ryan A Hankins; Annerleim Walton-Diaz; Hong Truong; Joanna Shih; Gennady Bratslavsky; Peter A Pinto; W Marston Linehan; Adam R Metwalli Journal: Int Urol Nephrol Date: 2016-08-11 Impact factor: 2.370
Authors: Daniel R Crooks; Nunziata Maio; Martin Lang; Christopher J Ricketts; Cathy D Vocke; Sandeep Gurram; Sevilay Turan; Yun-Young Kim; G Mariah Cawthon; Ferri Sohelian; Natalia De Val; Ruth M Pfeiffer; Parthav Jailwala; Mayank Tandon; Bao Tran; Teresa W-M Fan; Andrew N Lane; Thomas Ried; Darawalee Wangsa; Ashkan A Malayeri; Maria J Merino; Youfeng Yang; Jordan L Meier; Mark W Ball; Tracey A Rouault; Ramaprasad Srinivasan; W Marston Linehan Journal: Sci Signal Date: 2021-01-05 Impact factor: 8.192
Authors: Anna K Paschall; Moozhan Nikpanah; Faraz Farhadi; Elizabeth C Jones; Paul G Wakim; Andrew J Dwyer; Rabindra Gautam; Maria J Merino; Ramaprasad Srinivasan; W Marston Linehan; Ashkan A Malayeri Journal: Clin Imaging Date: 2020-06-09 Impact factor: 1.605
Authors: Daniel M Geynisman; Jodi K Maranchie; Mark W Ball; Gennady Bratslavsky; Eric A Singer Journal: Urol Oncol Date: 2021-06-04 Impact factor: 2.954